CareDx (NASDAQ:CDNA) Director Hannah Valantine Sells 12,103 Shares

CareDx, Inc. (NASDAQ:CDNA) Director Hannah Valantine sold 12,103 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.11, for a total value of $279,700.33. Following the transaction, the director owned 36,686 shares in the company, valued at $847,813.46. The trade was a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Stock Performance

Shares of CareDx stock traded down $0.83 on Tuesday, reaching $23.25. 938,029 shares of the company’s stock were exchanged, compared to its average volume of 719,498. The company has a market capitalization of $1.20 billion, a P/E ratio of -145.31 and a beta of 2.49. CareDx, Inc. has a 52 week low of $10.96 and a 52 week high of $24.85. The firm’s 50-day moving average is $20.93 and its two-hundred day moving average is $19.66.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.23. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The firm had revenue of $117.70 million for the quarter, compared to analysts’ expectations of $102.03 million. During the same period in the prior year, the business earned $0.09 EPS. The company’s revenue for the quarter was up 39.3% compared to the same quarter last year. On average, analysts expect that CareDx, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CDNA has been the subject of a number of analyst reports. Wall Street Zen raised CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CareDx in a research report on Wednesday, May 27th. Wells Fargo & Company raised their target price on CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Finally, BTIG Research raised their target price on CareDx from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CareDx has an average rating of “Hold” and an average price target of $25.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CDNA. Goldman Sachs Group Inc. boosted its stake in CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after purchasing an additional 170,504 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of CareDx by 11.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock valued at $2,378,000 after acquiring an additional 13,619 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of CareDx by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock valued at $1,340,000 after acquiring an additional 20,028 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of CareDx during the 2nd quarter valued at about $1,822,000. Finally, Nebula Research & Development LLC bought a new stake in shares of CareDx during the 2nd quarter valued at about $281,000.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.